Publications
Salami A, Adiele U, Coate G, Diolaiti M, Chen H, Lu J, Ashworth A, Patil M, Fleishman JS, Ramaraju A, Patel A, Patel H, Patel K, Murakami M, Ambudkar SV, Talele TT. Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorganic chemistry. 2025. PMID: 40945025
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40906970
Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson SA, Butte AJ. An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Blood advances. 2025. PMID: 40902085
Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson SA, Butte AJ. An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Blood advances. 2025. PMID: 40902085
Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40902132
Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40902132
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO precision oncology. 2025. PMID: 40893049
Benson AB, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Brown DB, Burgoyne A, Castellanos J, Cloyd J, Cullinan D, Franses J, Glazer ES, Harris W, Iyer R, Jennings L, Kelley RK, Khan S, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stein S, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Yano M, Yopp A, Zhao K, Schonfeld R, Hochstetler C. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40930144
Riely GJ, Wood DE, Aisner DL, Loo BW, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Mendez ALR, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Gregory K, Hang L. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40930154
Jang A, Tripathi N, Lanka SM, Kumar HLS, Jain P, Calaway A, Shoag JE, Vince R, Mendiratta P, Rao S, Garcia JA, Brown JR, Koshkin VS, Campbell MT, Singh P, Barata PC. Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? The oncologist. 2025. PMID: 40828887
Schettini F, Nucera S, Di Grazia G, Giudici F, Strina C, Milani M, Tancredi R, Conte B, Criscitiello C, Giuliano M, Lambertini M, Sánchez-Bayona R, Pascual T, Arpino G, Del Mastro L, Vigneri P, Cristofanilli M, Rugo HS, Gennari A, Curigliano G, Generali D. Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. JNCI cancer spectrum. 2025. PMID: 40796258
Sirohi D, Cornelia Ding CK, Stohr BA, Balassanian R, Vohra P, Aggarwal R, Chan E, Greenland NY. The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies. Cancer cytopathology. 2025. PMID: 40847760
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO open. 2025. PMID: 40896879
Sandler T, Manglicmot S, Mullen KM, Shah N, Philip J. Pragmatic Use of Minimal Common Oncology Data Elements and Observational Medical Outcomes Partnership at an Academic Medical Center. JCO clinical cancer informatics. 2025. PMID: 40882163
Kwong K, Pan Y, Morales J, Watson M, Allegakoen DV, Lee AG, Bivona TG, Wipf P, Guerriero CJ, Brodsky JL, Sabnis AJ. In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma. Oncotarget. 2025. PMID: 40879698
Yadav P, Gómez Ortega J, Dabral P, Tamaki W, Chien C, Chang KC, Biswas N, Pan S, Nilsson J, Yin X, Bhattacharyya A, Boostanpour K, Jujaray T, Wang JT, Tsukui T, Molina CJ, Auyeung VC, Sheppard D, Li B, Maishan M, Taenaka H, Matthay MA, Muramatsu R, Maliskova L, Ghosh A, Eckalbar WL, Molofsky AB, Tamaki SJ, Bivona TG, Abate AR, Wagner A, Pillai SK, Wolters PJ, Tharp KM, Bhattacharya M. Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis. The Journal of clinical investigation. 2025. PMID: 40875483
Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US. Blood advances. 2025. PMID: 40875591
Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US. Blood advances. 2025. PMID: 40875591
Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, I-SPY 2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, Veer LJV', Rosenbluth JM. Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies. bioRxiv : the preprint server for biology. 2025. PMID: 40909537
Ramesh A, Ko A, Patel PK, Reddy RC, Parel JG, Parel PM, Quan T, Abraham T, Mesfin A. Early Percutaneous Kyphoplasty Is Associated with Reduced Risk of Subsequent Thoracic Vertebral Compression Fracture. Spine surgery and related research. 2025. PMID: 41695905